U.S. markets closed
  • S&P 500

    4,397.94
    -84.79 (-1.89%)
     
  • Dow 30

    34,265.37
    -450.02 (-1.30%)
     
  • Nasdaq

    13,768.92
    -385.10 (-2.72%)
     
  • Russell 2000

    1,987.92
    -36.12 (-1.78%)
     
  • Crude Oil

    86.29
    -0.61 (-0.70%)
     
  • Gold

    1,836.10
    -6.50 (-0.35%)
     
  • Silver

    24.34
    -0.37 (-1.50%)
     
  • EUR/USD

    1.1355
    +0.0037 (+0.33%)
     
  • 10-Yr Bond

    1.7470
    -0.0860 (-4.69%)
     
  • GBP/USD

    1.3546
    -0.0055 (-0.40%)
     
  • USD/JPY

    113.6550
    -0.4450 (-0.39%)
     
  • BTC-USD

    36,178.32
    -4,887.46 (-11.90%)
     
  • CMC Crypto 200

    870.86
    +628.18 (+258.85%)
     
  • FTSE 100

    7,494.13
    -90.88 (-1.20%)
     
  • Nikkei 225

    27,522.26
    -250.67 (-0.90%)
     

3 Penny Stocks Insiders Are Buying

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • FTK
  • EMMA
  • OPXS

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Emmaus Life Sciences

The Trade: Emmaus Life Sciences, Inc. (OTC: EMMA) Chairman and CEO Yutaka Niihara acquired a total of 9701 shares at an average price of $1.55. To acquire these shares, it cost $15,021.55.

What’s Happening: The company’s stock has jumped over 18% since the start of the year.

What Emmaus Life Sciences Does: Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies primarily for rare and orphan diseases.

Flotek Industries

The Trade: Flotek Industries, Inc. (NYSE: FTK) CEO and President John Gibson Jr acquired a total of 2000 shares shares at an average price of $1.37. The insider spent $2,740.00 to buy those shares.

What’s Happening: The company, last month, results for its second quarter.

What Flotek Industries Does: Flotek Industries delivers chemistry-based technology solutions for energy, industrial, and consumer applications.

Optex Systems

The Trade: Optex Systems Holdings, Inc (OTC: OPXS) Director Dale E Lehmann acquired a total of 23158 shares at an average price of $1.50. To acquire these shares, it cost $34,766.50.

What’s Happening: The company’s shares gained around 5% over the previous month.

What Optex Systems Does: Optex Systems Holdings manufactures optical sighting systems and assemblies for the U.S. Department of Defense, foreign military applications, and commercial markets.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.